Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms REVOLVE
- Sponsors Celgene Corporation
- 11 Jan 2022 This trial has been completed in Norway (End date: 2017-10-19) according to European Clinical Trials Database record.
- 31 Jan 2018 This trial has been completed in Sweden (End date: 2017-10-19) according to European Clinical Trials Database record.
- 31 Jan 2018 This trial has been completed in Belgium (End date: 2018-01-05) according to European Clinical Trials Database record.